

## ICMJE DISCLOSURE FORM

Date: Aug 10, 2023

Your Name: Aizhen Yu

Manuscript Title: Newborn ornithine carbamyltransferase deficiency caused by new *OTC* gene mutations  
: a report of two cases and review of the literature on phenotype and genotype

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<i>Basic Research Program from Shenzhen Science and Technology Innovation Commission (JCYJ20180228175137465)</i>	<b>Payments were made to my institution</b>
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	____ None	
3	Royalties or licenses	<i>the TaKaRa Ex Taq Hot Start kit of Dalian Bao Biological Co., Ltd.(Dalian, China),</i> <i>the first-generation sequencing experiment in Sangon Biotech (Shanghai, China)</i>	None None
4	Consulting fees	____ None	
5	Payment or honoraria for	____ None	

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

**Please summarize the above conflict of interest in the following box:**

Basic Research Program from Shenzhen Science and Technology Innovation Commission (JCYJ20180228175137465), Payments.  
the TaKaRa Ex Taq Hot Start kit of Dalian Bao Biological Co., Ltd.(Dalian, China), NO Payments.  
*the first-generation sequencing experiment in Sangon Biotech (Shanghai, China), NO Payments.*

**Please place an "X" next to the following statement to indicate your agreement:**

  X   I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date: Aug 10, 2023

Your Name: Di Gao

Manuscript Title: Newborn ornithine carbamyltransferase deficiency caused by new *OTC* gene mutations  
: a report of two cases and review of the literature on phenotype and genotype

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<i>Basic Research Program from Shenzhen Science and Technology Innovation Commission (JCYJ20180228175137465)</i>	<b>Payments were made to my institution</b>
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	____ None	
3	Royalties or licenses	<i>the TaKaRa Ex Taq Hot Start kit of Dalian Bao Biological Co., Ltd.(Dalian, China),</i> <i>the first-generation sequencing experiment in Sangon Biotech (Shanghai, China)</i>	None None
4	Consulting fees	____ None	
5	Payment or honoraria for	____ None	

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

**Please summarize the above conflict of interest in the following box:**

Basic Research Program from Shenzhen Science and Technology Innovation Commission (JCYJ20180228175137465), Payments.  
the TaKaRa Ex Taq Hot Start kit of Dalian Bao Biological Co., Ltd.(Dalian, China), NO Payments.  
*the first-generation sequencing experiment in Sangon Biotech (Shanghai, China), NO Payments.*

**Please place an “X” next to the following statement to indicate your agreement:**

  X   I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date: Aug 10, 2023

Your Name: Senyan Zeng

Manuscript Title: Newborn ornithine carbamyltransferase deficiency caused by new OTC gene mutations  
: a report of two cases and review of the literature on phenotype and genotype

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<i>Basic Research Program from Shenzhen Science and Technology Innovation Commission (JCYJ20180228175137465)</i>	Payments were made to my institution
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	____None	
3	Royalties or licenses	<i>the TaKaRa Ex Taq Hot Start kit of Dalian Bao Biological Co., Ltd.(Dalian, China),</i>	None
		<i>the first-generation sequencing experiment in Sangon Biotech (Shanghai, China)</i>	None
4	Consulting fees	____None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_____ None	
6	Payment for expert testimony	_____ None	
7	Support for attending meetings and/or travel	_____ None	
8	Patents planned, issued or pending	_____ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_____ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_____ None	
11	Stock or stock options	_____ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_____ None	
13	Other financial or non-financial interests	_____ None	

**Please summarize the above conflict of interest in the following box:**

Basic Research Program from Shenzhen Science and Technology Innovation Commission (JCYJ20180228175137465), Payments.  
the TaKaRa Ex Taq Hot Start kit of Dalian Bao Biological Co., Ltd.(Dalian, China), NO Payments.  
*the first-generation sequencing experiment in Sangon Biotech (Shanghai, China)*, NO Payments.

**Please place an “X” next to the following statement to indicate your agreement:**

  X   I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date: Aug 10, 2023

Your Name: Lingzhu Huang

Manuscript Title: Newborn ornithine carbamyltransferase deficiency caused by new *OTC* gene mutations  
: a report of two cases and review of the literature on phenotype and genotype

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<i>Basic Research Program from Shenzhen Science and Technology Innovation Commission (JCYJ20180228175137465)</i>	<b>Payments were made to my institution</b>
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	____None	
3	Royalties or licenses	<i>the TaKaRa Ex Taq Hot Start kit of Dalian Bao Biological Co., Ltd.(Dalian, China),</i>	None
		<i>the first-generation sequencing experiment in Sangon Biotech (Shanghai, China)</i>	None
4	Consulting fees	____None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

**Please summarize the above conflict of interest in the following box:**

Basic Research Program from Shenzhen Science and Technology Innovation Commission (JCYJ20180228175137465), Payments.  
the TaKaRa Ex Taq Hot Start kit of Dalian Bao Biological Co., Ltd.(Dalian, China), NO Payments.  
*the first-generation sequencing experiment in Sangon Biotech (Shanghai, China)*, NO Payments.

**Please place an “X” next to the following statement to indicate your agreement:**

  X   I certify that I have answered every question and have not altered the wording of any of the questions on this form.



## ICMJE DISCLOSURE FORM

Date: Aug 10, 2023

Your Name: Fuman Jiang

Manuscript Title: Newborn ornithine carbamyltransferase deficiency caused by new *OTC* gene mutations  
: a report of two cases and review of the literature on phenotype and genotype

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<i>Basic Research Program from Shenzhen Science and Technology Innovation Commission (JCYJ20180228175137465)</i>	<b>Payments were made to my institution</b>
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	____ None	
3	Royalties or licenses	<i>the TaKaRa Ex Taq Hot Start kit of Dalian Bao Biological Co., Ltd.(Dalian, China),</i> <i>the first-generation sequencing experiment in Sangon Biotech (Shanghai, China)</i>	None None
4	Consulting fees	____ None	
5	Payment or honoraria for	____ None	

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	Shenzhen Jingke Genetic Science and Technology Co. Ltd, Shenzhen, China	

**Please summarize the above conflict of interest in the following box:**

Basic Research Program from Shenzhen Science and Technology Innovation Commission (JCYJ20180228175137465);  
the TaKaRa Ex Taq Hot Start kit of Dalian Bao Biological Co., Ltd.(Dalian, China), NO Payments;  
*the first-generation sequencing experiment in Sangon Biotech (Shanghai, China)*, NO Payments;  
Fuman Jiang is from Shenzhen Jingke Genetic Science and Technology Co. Ltd, Shenzhen, China.

**Please place an "X" next to the following statement to indicate your agreement:**

  X   I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date: Aug 10, 2023

Your Name: Xue Feng

Manuscript Title: Newborn ornithine carbamyltransferase deficiency caused by new OTC gene mutations  
: a report of two cases and review of the literature on phenotype and genotype

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<i>Basic Research Program from Shenzhen Science and Technology Innovation Commission (JCYJ20180228175137465)</i>	<b>Payments were made to my institution</b>
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	<i>the TaKaRa Ex Taq Hot Start kit of Dalian Bao Biological Co., Ltd.(Dalian, China),</i>	None
		<i>the first-generation sequencing experiment in Sangon Biotech (Shanghai, China)</i>	None

4	Consulting fees	___ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

**Please summarize the above conflict of interest in the following box:**

Basic Research Program from Shenzhen Science and Technology Innovation Commission (JCYJ20180228175137465), Payments.  
the TaKaRa Ex Taq Hot Start kit of Dalian Bao Biological Co., Ltd.(Dalian, China), NO Payments.  
*the first-generation sequencing experiment in Sangon Biotech (Shanghai, China), NO Payments.*

**Please place an “X” next to the following statement to indicate your agreement:**

  X   I certify that I have answered every question and have not altered the wording of any of the questions on this form.